1. Goals of Therapy in Relapsed CLL

2. Program Objectives

3. Treatment Goals With CIT

4. Considering the Effects of TEAEs and Comorbidities on Treatment Goals

5. Measures of Remission in CLL

6. Challenges of Clinical Measures of Remission

7. MRD as an Objective Measure to Predict PFS

8. MRD Negativity: Standardization of Threshold and Techniques

9. PB vs BM MRD Assessment

10. MRD Negativity vs Durable Disease Control

11. Predicting Disease Progression After MRD Negativity

12. MRD Negativity as an Endpoint in CLL Trials

13. MRD Negativity With Ibrutinib ± Rituximab

14. MURANO: Potential for Time-Limited Therapy

15. VenR: Post Treatment Relapse

16. MURANO: MRD Kinetics

17. CLARITY: MRD Negativity With Venetoclax Plus Ibrutinib

18. Achieving MRD Negativity With Intensive Combination Therapy: Clinical Considerations

19. MRD Negativity With Venetoclax Plus Anti-CD20 Antibody

20. PI3 Kinase Inhibitors: Considerations

21. Minimizing TLS Risk With Venetoclax

22. Next-Generation BTK Inhibitors

23. Looking Ahead

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)